Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-10-6
pubmed:abstractText
To evaluate the safety and efficacy of a modified version of cyclophosphamide, doxorubicin, vincristine, prednisone (pirarubicin, cyclophosphamide, vincristine, and prednisone [THP-COP]) plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0360-3016
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
847-52
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:15465202-Adolescent, pubmed-meshheading:15465202-Adult, pubmed-meshheading:15465202-Aged, pubmed-meshheading:15465202-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15465202-Combined Modality Therapy, pubmed-meshheading:15465202-Cyclophosphamide, pubmed-meshheading:15465202-Doxorubicin, pubmed-meshheading:15465202-Female, pubmed-meshheading:15465202-Head and Neck Neoplasms, pubmed-meshheading:15465202-Humans, pubmed-meshheading:15465202-Lymphoma, B-Cell, pubmed-meshheading:15465202-Lymphoma, Non-Hodgkin, pubmed-meshheading:15465202-Lymphoma, T-Cell, pubmed-meshheading:15465202-Male, pubmed-meshheading:15465202-Middle Aged, pubmed-meshheading:15465202-Neoplasm Staging, pubmed-meshheading:15465202-Pilot Projects, pubmed-meshheading:15465202-Prednisone, pubmed-meshheading:15465202-Recurrence, pubmed-meshheading:15465202-Survival Rate, pubmed-meshheading:15465202-Vincristine
pubmed:year
2004
pubmed:articleTitle
Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
pubmed:affiliation
Department of Radiology, Hokkaido University School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8648, Japan. trout@radi.med.hokudai.ac.jp
pubmed:publicationType
Journal Article